



Short Communication

Efficacy of ASP2151, a helicase–primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo

Takehiro Himaki^a, Yumi Masui^a, Koji Chono^b, Tohru Daikoku^a, Masaya Takemoto^a, Bo Haixia^a, Tomoko Okuda^a, Hiroshi Suzuki^b, Kimiyasu Shiraki^{a,*}^a Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan^b Drug Discovery Research, Astellas Pharma Inc., Miyukigaoka 21, Tsukuba, Ibaraki 305-8585, Japan

ARTICLE INFO

Article history:

Received 14 August 2011

Revised 23 November 2011

Accepted 26 November 2011

Available online 4 December 2011

Keywords:

Herpes simplex viruses

Thymidine kinase

ASP2151

Helicase–primase inhibitor

Resistance

Acyclovir

ABSTRACT

ASP2151 was developed as a novel inhibitor of herpes simplex virus (HSV) and varicella-zoster virus helicase–primase. The anti-HSV activity of ASP2151 toward a clinical HSV isolate with acyclovir (ACV)-resistant/thymidine kinase (TK)-deficiency was characterized in vitro and in vivo using a plaque reduction assay and the ear pinna infection in mice. The IC₅₀ ranged from 0.018 to 0.024 µg/ml, indicating the susceptibility of TK-deficient HSV-2 was similar to that of wild-type HSV-2 strains. Anti-HSV activity of ASP2151 in vivo was evaluated in mice infected with wild-type HSV-2 and TK-deficient HSV-2. ASP2151 significantly reduced the copy numbers of wild-type HSV-2 and TK-deficient HSV-2 at the inoculation ear pinna, while valacyclovir significantly reduced the copy number of wild type HSV-2 but not that of TK-deficient HSV-2 in the inoculated ear pinna. Thus, ASP 2151 showed therapeutic efficacy in mice infected with both wild-type and TK-deficient HSV-2. In conclusion, ASP2151 is a promising novel herpes helicase–primase inhibitor that indicates the feasibility of ASP2151 for clinical application for the treatment of HSV infections, including ACV-resistant/TK-deficient HSV infection.

© 2011 Elsevier B.V. All rights reserved.

Since the late 1970s, synthetic nucleoside analogues targeting viral DNA synthesis such as acyclovir (ACV), penciclovir, valacyclovir, and famciclovir have been developed and provided for the treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. However, the emergence of ACV-resistant HSV has been observed during prolonged ACV treatment (Balfour, 1983; Balfour et al., 1994; Burns et al., 1982; Chakrabarti et al., 2000; Chen et al., 2000; Crumpacker et al., 1982; Erlich et al., 1989; Gupta et al., 2000; Sacks et al., 1989; Shimada et al., 2007; Wade, 1993). Although recurrence of ACV-resistant HSV is not common, there are reports of current lesions caused by ACV-resistant virus in immunocompromised patients during ACV therapy (Morfin et al., 2000a,b; Safrin et al., 1991; Saijo et al., 2002; Sasadeusz and Sacks, 1996; Shimada et al., 2007). Thymidine kinase (TK)-deficient mutants resistant to ACV exhibit attenuation in the mouse model (Field and Darby, 1980), but some TK-deficient HSV cause progressive diseases in humans, and preserve pathogenicity in mice (Erlich et al., 1989; Kaplowitz et al., 1991; Sacks et al., 1989; Shimada et al., 2007; Swetter et al., 1998). The limitations of the current therapies highlight the need to develop novel anti-herpes drugs with potent antiviral activity based on alternative mechanisms of action.

HSV has variety of HSV-dependent enzymes, including protease and protein kinase, those are involved in the metabolism of nucleotides, DNA, and synthesis of DNA. Recently, there have been reports of newly synthesized selective inhibitors targeting these HSV-dependent enzymes. ASP2151 (amenamivir, Fig. 1) is an anti-herpes agent that targets the helicase–primase complex and reportedly has antiviral activity against wild-type HSV-1 and -2 and VZV in vitro (Chono et al., 2010). It is important to assess the activity of ASP2151 against ACV-resistant HSV for development of novel therapeutics. We have a paired clinical isolates with TK-positive and TK-deficient HSV-2 isolated from the genital lesion and the whitlow of the same patient, respectively (Shimada et al., 2007) and the paired clinical isolates which shows pathogenicity in mice were used for the efficacy comparison of ACV and ASP2151 to TK-deficient HSV-2 infection.

ASP2151 was synthesized by Astellas Pharma Inc. (Tokyo, Japan), and acyclovir was purchased from Sigma, St. Louis, MO. Both were dissolved in dimethylsulfoxide just before use.

To evaluate the antiviral efficacy of ASP2151, a plaque reduction assay was performed as described previously (Kurokawa et al., 1993; Miwa et al., 2005; Okuda et al., 2004; Yoshida et al., 2005). Briefly, Vero cells in 6 cm petri dishes were infected with 100 plaque-forming units of three HSV-2 strains, the wild-type HSV-2 (OOM strain), genital isolate (TK-positive), and whitlow isolate (TK-deficient), for 1 h. Then the cells were overlaid with 0.8%

* Corresponding author. Tel.: +81 76 434 7255; fax: +81 74 434 5020.

E-mail address: kshiraki@med.u-toyama.ac.jp (K. Shiraki).




Fig. 1. Structure of ASP2151 (amenamevir).

nutrient methylcellulose medium containing various concentrations of the test compounds (ACV alone: 0, 0.25, 0.5, 1, or 2 $\mu\text{g}/\text{ml}$ or ASP2151 alone: 0, 0.0015, 0.003, 0.006, 0.012, 0.024, or 0.048 $\mu\text{g}/\text{ml}$), and 3 days later, fixed with 5% neutral formalin and stained with methylene blue. The number of plaques was counted under a dissecting microscope. The 50% inhibitory concentration for plaque formation (IC_{50}) was defined as the concentration at which the plaque number decreased to half of that in cells cultured without the addition of antiviral drugs. The IC_{50} was determined by using the computer program Microplate Manager III (BioRad, Hercules, CA).

We also investigated the efficacy of ASP2151 on wild-type HSV-2 and TK-deficient HSV-2 infection in a mouse ear pinna infection model. Female BALB/c mice (7 weeks old) were purchased from Sankyo Labs Service Co. Ltd., Tokyo, Japan. All animal experimental procedures conformed to the National Institute of Health Guide for the Care and Use of Laboratory Animals and the Experimentation Guidelines of the University of Toyama. The ear pinna was used to evaluate the temperature-sensitive pathogenicity of the TK-deficient whitlow isolate because this clinical isolate causes cutaneous lesions on the cooler ear pinna but not in the skin of the warmer midflank (Shimada et al., 2007). Both ear pinnas were scratched with a bundle of 27-gauge needles and left and right ear pinnas were infected by spreading 5 μl of viral solution containing 2.5×10^4 PFU at 37 °C of genital (TK-positive) and whitlow (TK-deficient) isolates, respectively. ASP2151 was dissolved in 25% (v/v) PEG400 and 25% (v/v) Cremophor EL solution before use. ASP2151 (3 mg/kg per dose), valacyclovir (30 mg/kg per dose), or the vehicle as a control were orally administered by gavage at 2 h before infection and twice daily for 8 days until the ear pinnas were harvested.

The amount of virus in the ear pinna was assessed by quantitative PCR (Aldea et al., 2002; Phromjai et al., 2007; Shimada et al., 2007). Briefly, all mice were euthanized 8 days after HSV-2 infection, and ear pinnas were collected and weighed. DNA was extracted from the ear pinnas using a nucleotide extraction kit (Qiagen, Tokyo, Japan), and the amount of HSV-2 DNA was monitored by real-time PCR based on SYBR green incorporation using 5'-GCTCGAGTGCAGAAA-AACGTTTC-3' and 5'-CGGGGCGCTCGGCTAAC-3' as PCR primers for amplification of UL30 encoding the DNA polymerase gene. To normalize each of the DNA extracts, eight serial HSV-2 genomic DNA sequences with known copy numbers were used as a standard control. The copy numbers of the ear pinna HSV-2 DNA suspended in 20 μl of total reaction volume were quantified using SYBR Premix Ex Taq (Takara Bio Inc., Kyoto, Japan) using a Thermal Cycler Dice TP800 (Takara Bio) and Thermal Cycler Dice Real Time System Software and expressed as the number of copies of HSV-2 DNA per 1 mg of ear pinna.

Statistical analysis of the HSV-2 DNA copy numbers among treatment groups was accomplished using one-way analysis of variance (ANOVA) and Fisher's Protected Least Significant Difference (PLSD) test. The change of body weight in the treatment groups was evaluated by one-way ANOVA followed by Fisher's PLSD as the post-hoc test. Statistical differences were considered significant at $P < 0.05$.

The susceptibilities of viruses to ACV and ASP2151 are shown in Table 1. The IC_{50} of ACV was similar in clinical isolates of HSV-2

Table 1

Susceptibility to anti-herpetic drugs of OOM strain and paired clinical isolates of HSV-2 ($\mu\text{g}/\text{ml}$).

Strain	Acyclovir	ASP2151
OOM	0.730 ± 0.169	0.022 ± 0.002
Genital isolate (TK-positive)	0.666 ± 0.115	0.024 ± 0.003
Whitlow isolate (TK-deficient)	37.510 ± 5.018	0.018 ± 0.004

The antiviral activity (IC_{50}) of acyclovir and ASP2151 toward virus strains are expressed as the mean ($\mu\text{g}/\text{ml}$) \pm S.E. of four independent plaque reduction assays. The whitlow isolate was significantly resistant to acyclovir ($P < 0.0005$) compared to OOM and a genital isolate by the Student's *t*-test.

(OOM) and the genital isolate, but the ACV-resistant/TK-deficient HSV-2 had about 50 times lower susceptibility to acyclovir than the other HSV-2 strains. On the other hand, the IC_{50} of ASP2151 was similar for all three HSV-2 strains including an ACV-resistant/TK-deficient HSV-2, and the IC_{50} to ASP2151 was about 30 times lower than that to ACV.

Fig. 2 shows the changes in body weight of the three groups. The body weight loss was significantly less in the ASP2151 group than the vehicle group at 5–6 days after virus infection ($P < 0.05$). However, there was no significant difference between the ASP2151 and valacyclovir treatment groups.

The efficacy of ASP2151 and valacyclovir was evaluated by the reduction in the number of copies in the infected ear pinna. The amounts of virus in the ear pinna in mouse groups treated with ASP2151, valacyclovir, and vehicle are shown in Fig. 3. The numbers of virus copies of the TK-positive HSV-2 in the ASP2151 and valacyclovir treatment groups were significantly lower than those in the vehicle groups ($P = 0.019$ and $P = 0.005$, respectively), but no significant difference between ASP2151 and valacyclovir treatment groups was observed. On the other hand, the numbers of virus copies of TK-deficient HSV-2 in the ASP2151 treatment group was significantly lower than those of vehicle and valacyclovir treatment groups ($P = 0.001$ and $P = 0.009$, respectively). There was no significant difference between the vehicle and valacyclovir treatment groups. Thus, ASP2151 was effective against TK-deficient HSV-2, while valacyclovir was not.

ASP2151 showed potent anti-HSV activity not only against the wild-type HSV-2 but also against ACV-resistant/TK-deficient HSV-2 both in vitro and in vivo. In a guinea pig model of genital herpes using wild-type HSV-2, ASP2151 showed the superior to valacyclovir in both potency and efficacy (Katsumata et al.,




Fig. 2. Changes in body weight of mice in ASP2151, valacyclovir, and vehicle treatment groups. Open squares (ASP2151, $n = 9$) and closed circles (valacyclovir, $n = 10$) and open triangles (vehicle, $n = 10$) indicate the mean \pm S.D. of weight loss of each group, respectively. The body weight was measured at the same time daily using a finely calibrated animal-weighing balance. * $P < 0.05$ by comparison of ASP2151 group versus vehicle group at 5–6 days after infection by the one-way ANOVA followed by Fisher's PLSD.




Fig. 3. Comparison of copy numbers per 1 mg of ear pinna infected with the TK-positive genital isolate (left ear pinna) and TK-deficient whitlow isolate (right ear pinna) in mice treated with ASP2151 (3 mg/kg per dose, $n = 9$), valacyclovir (30 mg/kg per dose, $n = 10$), or vehicle ($n = 10$). The copy number showed the mean copy number \pm S.D. of HSV-2 DNA. The data was analyzed using one-way ANOVA, followed by Fisher's PLSD. $P < 0.05$ and $P < 0.01$ indicate significant differences between groups.

2011). Although the action of ASP2151 against ACV-resistant/TK-deficient HSV-2 was expected from the different acting sites on different enzymes between acyclovir/valacyclovir and ASP2151, this study clearly demonstrated the efficacy of ASP2151 against both wild-type and TK-deficient HSV. Thus the demonstration of the therapeutic efficacy of ASP2151 against ACV-resistant/TK-deficient HSV-2 was accomplished by a valuable clinical TK-deficient HSV-2 isolate that preserved pathogenicity in mice. The IC_{50} of ASP2151 against VZV was lower than that of acyclovir, and the IC_{50} of ASP2151 against HSV was similarly lower than that of acyclovir (Chono et al., 2010). Other helicase–primase inhibitors, such as BILS 179 BS and BAY 57-1293, have been reported to possess comparable antiviral potency against HSV-1 and HSV-2 (Spector et al., 1998; Crute et al., 2002; Kleymann et al., 2002) but not against VZV (Chono et al., 2010). The clinical efficacy of ASP2151 was confirmed in Phase II clinical studies conducted in patients with herpes zoster (NCT ID: NCT00487682) and recurrent genital herpes (NCT ID: NCT00486200) (unpublished results).

In conclusion, ASP2151 showed therapeutic efficacy in mice infected with a TK-deficient HSV-2 as it did with TK-positive HSV-2, indicating that ASP2151 may serve as a therapeutic option for HSV and VZV infections even against ACV-resistant/TK-deficient HSV.

Acknowledgments

We thank Ms. Katherine Ono for editing the manuscript. This work was partly supported by Astellas Pharma Inc.

References

- Aldea, C., Alvarez, C.P., Folgueira, L., Delgado, R., Otero, J.R., 2002. Rapid detection of herpes simplex virus DNA in genital ulcers by real-time PCR using SYBR green I dye as the detection signal. *J. Clin. Microbiol.* 40, 1060–1062.
- Balfour Jr., H.H., 1983. Resistance of herpes simplex to acyclovir. *Ann. Intern. Med.* 98, 404–406.
- Balfour Jr., H.H., Benson, C., Braun, J., Cassens, B., Erice, A., Friedman-Kien, A., Klein, T., Polsky, S., Safran, S., 1994. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. *J. Acquir. Immune Defic. Syndr.* 7, 254–260.
- Burns, W.H., Saral, R., Santos, G.W., Laskin, O.L., Lietman, P.S., McLaren, C., Barry, D.W., 1982. Isolation and characterization of resistant herpes simplex virus after acyclovir therapy. *Lancet* 1, 421–423.
- Chakrabarti, S., Pillay, D., Ratcliffe, D., Cane, P.A., Collingham, K.E., Milligan, D.W., 2000. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. *J. Infect. Dis.* 181, 2055–2058.
- Chen, Y., Scieux, C., Garrait, V., Socie, G., Rocho, V., Molina, J.M., Thouvenot, D., Morfin, F., Hocqueloux, L., Garderet, L., Esperou, H., Selimi, F., Devergie, A., Leleu, G., Aymard, M., Morinet, F., Gluckman, E., Ribaud, P., 2000. Resistant herpes

- simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. *Clin. Infect. Dis.* 31, 927–935.
- Chono, K., Katsumata, K., Kontani, T., Kobayashi, M., Sudo, K., Yokota, T., Konno, K., Shimizu, Y., Suzuki, H., 2010. ASP2151, a novel helicase–primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. *J. Antimicrob. Chemother.* 65, 1733–1741.
- Crumpacker, C.S., Schnipper, L.E., Marlowe, S.I., Kowalsky, P.N., Hershey, B.J., Levin, M.J., 1982. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. *N. Engl. J. Med.* 306, 343–346.
- Crute, J.J., Grygon, C.A., Hargrave, K.D., Simoneau, B., Faucher, A.M., Bolger, G., Kibler, P., Liuzzi, M., Cordingley, M.G., 2002. Herpes simplex virus helicase–primase inhibitors are active in animal models of human disease. *Nat. Med.* 8, 386–391.
- Erlich, K.S., Mills, J., Chatis, P., Mertz, G.J., Busch, D.F., Follansbee, S.E., Grant, R.M., Crumpacker, C.S., 1989. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. *N. Engl. J. Med.* 320, 293–296.
- Field, H.J., Darby, G., 1980. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. *Antimicrob. Agents Chemother.* 17, 209–216.
- Gupta, P., Leroux, C., Patterson, B.K., Kingsley, L., Rinaldo, C., Ding, M., Chen, Y., Kulka, K., Buchanan, W., McKeon, B., Montelaro, R., 2000. Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral Quasi species between blood and semen. *J. Infect. Dis.* 182, 79–87.
- Kaplowitz, L.G., Baker, D., Gelb, L., Blythe, J., Hale, R., Frost, P., Crumpacker, C., Rabinovich, S., Peacock Jr., J.E., Herndon, J., et al., 1991. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group. *JAMA* 265, 747–751.
- Katsumata, K., Chono, K., Sudo, K., Shimizu, Y., Kontani, T., Suzuki, H., 2011. Effect of ASP2151, a herpesvirus helicase–primase inhibitor, in a guinea pig model of genital herpes. *Molecules* 16, 7210–7223.
- Kleymann, G., Fischer, R., Betz, U.A., Hendrix, M., Bender, W., Schneider, U., Handke, G., Eckenberg, P., Hewlett, G., Pevzner, V., Baumeister, J., Weber, O., Henninger, K., Keldenich, J., Jensen, A., Kolb, J., Bach, U., Popp, A., Maben, J., Frappa, I., Haebich, D., Lockhoff, O., Rubsamen-Waigmann, H., 2002. New helicase–primase inhibitors as drug candidates for the treatment of herpes simplex disease. *Nat. Med.* 8, 392–398.
- Kurokawa, M., Ochiai, H., Nagasaka, K., Neki, M., Xu, H., Kadota, S., Sutardjo, S., Matsumoto, T., Namba, T., Shiraki, K., 1993. Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. *Antiviral Res.* 22, 175–188.
- Miwa, N., Kurosaki, K., Yoshida, Y., Kurokawa, M., Saito, S., Shiraki, K., 2005. Comparative efficacy of acyclovir and vidarabine on the replication of varicella-zoster virus. *Antiviral Res.* 65, 49–55.
- Morfin, F., Souillet, G., Bilger, K., Ooka, T., Aymard, M., Thouvenot, D., 2000a. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. *J. Infect. Dis.* 182, 290–293.
- Morfin, F., Thouvenot, D., Aymard, M., Souillet, G., 2000b. Reactivation of acyclovir-resistant thymidine kinase-deficient herpes simplex virus harbouring single base insertion within a 7 Gs homopolymer repeat of the thymidine kinase gene. *J. Med. Virol.* 62, 247–250.
- Okuda, T., Kurokawa, M., Matsuo, K., Honda, M., Niimura, M., Shiraki, K., 2004. Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus. *J. Med. Virol.* 72, 112–120.
- Phromjai, J., Aiba, N., Suzuki, M., Sato, H., Takahara, T., Kondo, S., Shiraki, K., 2007. Infection and direct injury in human hepatocyte explants and a hepatoblastoma cell line due to hepatiticomimetic (non-hepatitis) viruses. *J. Med. Virol.* 79, 413–425.
- Sacks, S.L., Wanklin, R.J., Reece, D.E., Hicks, K.A., Tyler, K.L., Coen, D.M., 1989. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? *Ann. Intern. Med.* 111, 893–899.
- Safran, S., Crumpacker, C., Chatis, P., Davis, R., Hafner, R., Rush, J., Kessler, H.A., Landry, B., Mills, J., 1991. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. *N. Engl. J. Med.* 325, 551–555.
- Saijo, M., Yasuda, Y., Yabe, H., Kato, S., Suzutani, T., De Clercq, E., Niikura, M., Maeda, A., Kurane, I., Morikawa, S., 2002. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus. *J. Med. Virol.* 68, 99–104.
- Sasadeusz, J.J., Sacks, S.L., 1996. Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type-2 herpes simplex virus: masked heterogeneity or reversion? *J. Infect. Dis.* 174, 476–482.
- Shimada, Y., Suzuki, M., Shirasaki, F., Saito, E., Sogo, K., Hasegawa, M., Takehara, K., Phromjai, J., Chuhjo, T., Shiraki, K., 2007. Genital herpes due to acyclovir-sensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient/temperature-sensitive virus. *J. Med. Virol.* 79, 1731–1740.
- Spector, F.C., Liang, L., Giordano, H., Sivaraja, M., Peterson, M.G., 1998. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. *J. Virol.* 72, 6979–6987.

- Swetter, S.M., Hill, E.L., Kern, E.R., Koelle, D.M., Posavad, C.M., Lawrence, W., Safrin, S., 1998. Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. *J. Infect. Dis.* 177, 543–550.
- Wade, J.C., 1993. Management of infection in patients with acute leukemia. *Hematol. Oncol. Clin. North Am.* 7, 293–315.
- Yoshida, Y., Li, Z., Kurokawa, M., Kawana, T., Imakita, M., Shiraki, K., 2005. Growth of herpes simplex virus in epidermal keratinocytes determines cutaneous pathogenicity in mice. *J. Med. Virol.* 75, 421–426.